Gyre Therapeutics, Inc. (GYRE) — 8-K Filings

8-K Filings (21)

• 8-K Filing — May 4, 2026
• Gyre Therapeutics, Inc. Files 8-K — Sep 10, 2025 Risk: low
  On September 10, 2025, Gyre Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's name from Catalyst Biosciences, Inc. to Gyre
• Gyre Therapeutics Files 8-K on Director/Officer Changes — Aug 22, 2025 Risk: medium
  Gyre Therapeutics, Inc. (formerly Catalyst Biosciences, Inc.) filed an 8-K on August 22, 2025, reporting events as of August 18, 2025. The filing covers the dep
• Gyre Therapeutics Files 8-K on Shareholder Vote — Jun 6, 2025 Risk: low
  Gyre Therapeutics, Inc. filed an 8-K on June 6, 2025, reporting on a matter submitted to a vote of security holders on June 4, 2025. The company, formerly known
• Gyre Therapeutics Enters Material Definitive Agreement — May 23, 2025 Risk: medium
  On May 22, 2025, Gyre Therapeutics, Inc. entered into a material definitive agreement. The company, formerly known as Catalyst Biosciences, Inc. and Targacept I
• Gyre Therapeutics Updates Corporate Address and Contact Info — May 22, 2025 Risk: low
  On May 22, 2025, Gyre Therapeutics, Inc. (formerly Catalyst Biosciences, Inc.) filed an 8-K report. The filing indicates a change in the company's principal exe
• Gyre Therapeutics Files 8-K — Apr 28, 2025 Risk: low
  On April 28, 2025, Gyre Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. Th
• Gyre Therapeutics Files 8-K on Financials — Mar 17, 2025 Risk: low
  On March 17, 2025, Gyre Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as we
• Gyre Therapeutics Files 8-K on Financials — Feb 18, 2025 Risk: low
  Gyre Therapeutics, Inc. filed an 8-K on February 18, 2025, reporting on its Results of Operations and Financial Condition as of February 14, 2025. The filing al
• Gyre Therapeutics Files 8-K with Officer/Director Changes — Jan 6, 2025 Risk: medium
  Gyre Therapeutics, Inc. filed an 8-K on January 6, 2025, reporting events as of December 31, 2024. The filing includes information on the departure of directors
• Gyre Therapeutics Files 8-K: Material Agreement & Exhibits — Nov 27, 2024 Risk: medium
  On November 27, 2024, Gyre Therapeutics, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial sta
• Gyre Therapeutics Appoints New CMO, Elects Director — Aug 8, 2024 Risk: medium
  Gyre Therapeutics, Inc. announced on August 6, 2024, the appointment of Dr. Jonathan G. Drachman as Chief Medical Officer and the election of Ms. Sarah E. Kelly
• Gyre Therapeutics Faces Nasdaq Delisting Warning — Jul 5, 2024 Risk: medium
  Gyre Therapeutics, Inc. announced on June 28, 2024, that it received a notification from Nasdaq on June 27, 2024, indicating a failure to meet the minimum bid p
• Gyre Therapeutics Changes Fiscal Year End — Jun 17, 2024 Risk: low
  Gyre Therapeutics, Inc. (formerly Catalyst Biosciences, Inc.) filed an 8-K on June 17, 2024, reporting a change in its fiscal year end to December 31st, effecti
• Gyre Therapeutics Files 8-K with Financials and Exhibits — May 30, 2024 Risk: low
  On May 30, 2024, Gyre Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Reg
• Gyre Therapeutics Files 8-K on Operations and Financials — May 9, 2024 Risk: low
  Gyre Therapeutics, Inc. filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing also includes financial statemen
• Acelyrin to Acquire Gyre Therapeutics for $1/Share + CVR — May 8, 2024 Risk: medium
  Gyre Therapeutics, Inc. announced on May 7, 2024, that it has entered into a definitive agreement to be acquired by Acelyrin, Inc. for approximately $1.00 per s
• Gyre Therapeutics Faces Nasdaq Delisting Warning — Mar 26, 2024 Risk: high
  Gyre Therapeutics, Inc. announced on March 22, 2024, that it received a notification from Nasdaq on March 22, 2024, indicating non-compliance with listing rules
• Gyre Therapeutics Files 8-K on Financials — Mar 26, 2024 Risk: low
  On March 26, 2024, Gyre Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as we
• Gyre Therapeutics Appoints New CMO and CSO — Mar 21, 2024 Risk: medium
  Gyre Therapeutics, Inc. announced on March 20, 2024, the appointment of Dr. Jonathan M. Roth as Chief Medical Officer and Dr. David M. Chang as Chief Scientific
• Gyre Therapeutics Files 8-K on Financial Condition & Regulation FD — Feb 14, 2024 Risk: low
  Gyre Therapeutics, Inc. filed an 8-K on February 14, 2024, reporting an event that occurred on February 8, 2024. The filing indicates disclosure related to 'Res

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX